Lastly, if your healthcare provider decides a Hers weight loss treatment plan is right for you, the medication will be shipped directly to you. Hers’ science-backed program combines customized medication with ongoing access to healthcare providers, meal plans and recipes, movement guides, and sleep support — available 100% online. In a January statement, the agency warned against people using compounded forms of weight loss drugs when FDA-approved versions are available. Investors are now focused on the company's upcoming financial results. My Globe health plan, through Blue Cross Blue Shield of Massachusetts, covers Zepbound with a $50 monthly copay. With the look and feel of a slick political attack ad, the commercial slams an American weight-loss industry “that feeds on our failure” and is “built to keep us sick and stuck.” "I, in no way condone nor support acts or threats of violence, antisemitism, or intimidation and there is absolutely no justification for violence on our campuses," Dudum wrote. He later walked back those comments days later, saying they were "misconstrued by some" after the company's stock dipped. “We are laser focused on increasing access to world-class personalized care in the highest impact areas of health and wellness,” said Dr. Patrick Carroll, Chief Medical Officer of Hims & Hers. To help solve the obesity crisis in America, successful weight loss solutions are critical to helping patients prosper. We’re just at the beginning of our weight journey along with our customers, and it’s exciting to see their tremendous success with Hims & Hers weight loss program. Our ability to provide access to tailored medications to meet each customer’s unique needs, combined with ongoing support through regular communication, compliance monitoring, and holistic lifestyle coaching, has been key to this success. Notably, customers who have tried other traditional weight loss methods have found success with our program. Beware of Marketing Hype “Clinicians who understand how supportive medication can be is one of the best parts of Noom! Lasting success depends on building healthier habits and having the right support system in place. The support you receive differs greatly between programs. Yes, behavior change plays a crucial role in long-term success, especially with GLP-1 medications. “At Hims & Hers, we are focused on bettering the health of Americans by making essential, life-changing care accessible,” Kenger said. According to television data and analytics firm EDO, four of the top 10 pharmaceutical advertisers during regular-season NFL games were touting diabetes and weight management drugs. It asserts that GLP-1 diabetes drugs, including Novo Nordisk-produced Ozempic and Wegovy, have been overpriced by shortages created within a system designed to keep the overweight and obese “sick and stuck.” Track-and-trace also prevents counterfeit drugs from entering the system.Introducing nutrition support subscriptions represents another example of our commitment to taking care of our customers’ health holistically.Titrated dosing and a dedicated care team can help customers manage these effects early.Clinical studies and real-world experiences show promising results for individuals seeking to manage their weight through these innovative treatments.Without insurance coverage, the cost of medications like Ozempic and Wegovy can run more than $1,000 a month.By combining these effects, GLP-1 injections create a multi-faceted approach to weight loss, addressing both physiological and behavioral aspects of obesity. Hims & Hers hopes its push for new patients will outlive the 15 minutes of fame characteristic of Super Bowl commercials. Our nutrition and meals plans are truly personalized through one-one conversations, not from clicking boxes of interest on a form. And, if telehealth is preferred, New Jersey Bariatric Center® offers it also with the back-up security of having a local physician in NJ if needed. New Wegovy®, first-order customers only, paid up front in full. Tackling the obesity epidemic in law enforcement. Serving more than 1.3 million active customers, ZAVA’s in-house medical team delivered nearly 2.3 million consultations in 2024 across the UK, Germany, France and Ireland - putting compassionate, clinically-robust healthcare in people’s hands 24/7. ZAVA is a leading digital health platform in Europe, on a mission to make high-quality, dependable healthcare accessible and affordable. “Together we’ll pair ZAVA’s trusted clinical services, established footprint, and deep understanding of the European healthcare landscape with the Hims & Hers experience to make affordable access to high-quality, personalized care the rule, not the exception. No two people are the same, so the Company provides access to personalized care designed for results. Since November 2023, Hims & Hers has provided its customers access to weight loss solutions. Because you can connect with a licensed healthcare provider through Hers, you can rest assured that if you are prescribed compounded semaglutide or oral medication kits, it will be legal and from U.S.-based pharmacies through valid prescriptions from licensed healthcare providers. “The goal to make change in one’s life is a journey, so we provide support through every step of the weight loss journey with a holistic, tailored program that takes their entire self into account.” The weight loss treatment plan is a comprehensive and customizable clinical approach specifically designed to help people achieve their individual weight-loss goals. The two are among a group of so-called GLP-1 drugs that have been approved to treat diabetes but have become tremendously popular for weight loss. Both companies offer GLP-1 access, but the way they structure support and behavioral guidance shapes the value you receive. By pairing prescription therapies with behavior change, coaching, and lasting habits, Noom helps people not only lose weight—but keep it off. Choosing a program with long-standing expertise and comprehensive support can make the difference between short-term results and progress that lasts. The company added that it will also sell brand-name versions of GLP-1 drugs, once supply rebounds. “I built healthy habits with coaching and lessons that make me confident I can maintain my weight loss long term.” “All of the Noom providers that I’ve met with have been exceptional and prescribed medications that are appropriate for my situation and health.” As one in eight people live with obesity, which increases the risk of diabetes, heart disease, and early mortality, the drugs have garnered a lot of attention as a way to help treat the condition. The demand for weight loss drugs, which can cost upwards of $1,000 per month before insurance, has skyrocketed, leading to nationwide shortages. As we continue our work to bring world class, personalized care to more people, our priority remains on the safety and success of each of our customers. With options ranging from compounded to brand-name medications, individuals can find a treatment that fits their needs and budget. EXCLUSIVE: Tecovas Makes Super Bowl Debut With Cinematic Fever Dream ‘True West’ That means a solution must focus on treating the whole person, not just prescribing a medication and hoping for the best. Weight loss is about more than medication, or even the number on the scale. For more information, please visit and Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. Only 10.3% of users reported side effects and less than 5% said those symptoms were severe enough to stop treatment. The GLP-1 offering generated more than $225 million in revenue for the company in 2024. In the company's quarterly call with investors on Monday, Chief Financial Officer Yemi Okupe said the scaling of the company's GLP-1 offering and its strategic pricing options were to blame. But the company's gross margin, or the profit left after accounting for the cost of goods sold, was 77%, disappointing analysts who were expecting 78.4%, according to StreetAccount. The company is tapping an opportunity to profit by focusing on Americans' desire to slim down. One study found patients regained about two-thirds of their weight loss within a year after stopping weekly semaglutide injections. Bear in mind that oral medications are compounded and are not FDA-approved, which also makes them unavailable in some states. Also, their oral medications are compounded medications and are not FDA-approved. You complete a health intake, message a licensed provider, and, if approved, receive medication and support delivered to your door. The ad begins with a barrage of statistics centered around obesity and obesity-related deaths in the U.S. Elizabeth Glowacki, an assistant teaching professor at Northeastern University, who focuses on health communication, message design, persuasion and mobile health, echoes much of that criticism. On its website, Hims & Hers advertises a price of $165 per month for weekly injections of compounded semaglutide. Hims & Hers also said in its statement that the company is “complying with existing law,” in response to Sens. Durbin and Marshall’s letter to the FDA. In response to Novo Nordisk's ad, Hims & Hers told ABC News in a statement it takes, “safety, quality, and transparency steps for every customer on our platform.” By recognizing these differences and tailoring your approach accordingly, both men and women can achieve sustainable, healthy weight loss that enhances overall well-being. The reality of his vs. hers weight loss reveals significant differences in how men and women lose weight, and understanding these differences is crucial for creating effective, personalized approaches to reaching your goals. The American Medical Association, the nation’s largest physician group, came out in support of a ban in 2015, citing TV advertising’s role in “inflating demand for new and more expensive drugs.” GLP-1 medications were originally developed to treat type-2 diabetes and obesity and went through extensive clinical trials before being approved. Noom also has a clinical obesity management solution called Noom Med that supports consumers and employers and includes medication management, education and nutrition and exercise tools. I feel like we can offer support on a platform that people trust already.” To lead the weight loss program, Hims & Hers appointed Dr. Craig Primack as the senior vice president of weight management. And the top desire for a weight loss plan, according to Americans, is “That it’s simple to follow.” For example, of the Americans surveyed, those with obesity are 50% more likely than individuals without obesity to skip work based on their weight, as well as 2.5X more likely to withdraw from activities, social plans, and goals. In fact, 85% of individuals with obesity say their weight has had a direct and negative impact on their day-to-day life as compared to 60% of survey respondents overall. Why Hims & Hers Health (HIMS) Stock Is Down Today By comparison, the Super Bowl ad for weight loss medications from direct-to-consumer telehealth company Hims & Hers released Tuesday is optimized to engage and infuriate. Hims & Hers, one of the largest publicly traded telehealth companies in the country, has supercharged its business in the last several months by offering compounded versions of the patented weight loss drugs known as GLP-1s. But compounded drugs can traditionally only be mass produced when the branded medications treatments are in shortage. Plus, an array of weight loss options from compounded GLP-1 injections to custom oral medication kits reviewed and prescribed by a licensed healthcare provider and/or a custom blend of doctor-trusted ingredients, each shown to promote weight loss. Hims & Hers in May started prescribing compounded semaglutide, the active ingredient in Novo Nordisk's GLP-1 weight loss medications Ozempic and Wegovy. With Noom Med, you get access to Noom’s award-winning behavior change program at no extra cost and users lose 48% more weight with Noom Med compared to medications alone. With GLP-1 medications becoming an important tool for weight loss, many people are looking for trusted guidance to navigate their options. “For too long the focus of weight loss has been size and pounds lost, when in reality, it should be about access, helping people find the best version of their health, and a system that is built for profit. From our more than 10 years of experience treating people in New Jersey with weight loss medications, we know what works. Analysts and market reports suggest that Hims & Hers is directly benefiting from the accessibility and pricing challenges plaguing branded drugs from both Novo Nordisk and its competitor, Eli Lilly.People respond differently to treatments, so as a physician, I wholeheartedly believe that providing personalized care is not just beneficial, but essential for achieving continued and meaningful, long-term success.Customers will need a prescription from their medical provider, based on what is "medically appropriate and necessary for each patient," the company said.These custom-prepared medications contain the same active ingredient as FDA-approved drugs but are produced at a fraction of the cost.“Together we’ll pair ZAVA’s trusted clinical services, established footprint, and deep understanding of the European healthcare landscape with the Hims & Hers experience to make affordable access to high-quality, personalized care the rule, not the exception.The company’s ability to sustain this momentum may depend on overcoming these credibility and compliance headwinds.Looser labeling requirements for compounded versions of GLP-1s can also lead to confusion about dosage, according to an FDA alert issued in July 2024.In a first-of-its-kind U.S. analysis of treatment plans, including compounded GLP-1s, customers taking a compounded GLP-1 reported losing an average of 20.9 pounds or 10.3% of initial body weight, within six months, while reporting a low rate of side effects. Consumers expect transparency, especially when dealing with prescription medications and weight-loss treatments that affect long-term health. These compounded drugs are not reviewed by the FDA for safety, strength, or effectiveness in the same way as branded medications. The agency found that certain promotional materials created the impression that compounded GLP-1 drugs were the same as FDA-approved medications such as semaglutide or tirzepatide. LifeMD, a direct-to-consumer company, announced a weight management program in June that offers access to GLP-1s if considered appropriate, as well as clinical support, coaching and education. These are all older drugs that support weight loss in combination with diet and exercise. Hims & Hers (HIMS) Q2 Revenue Jumps 73% Compounded GLP-1s contain the same active ingredients as branded medications, but they are made by specialty pharmacies and are not FDA-approved. Therefore, if you’re cost-sensitive and open to compounded meds, Hers can be a good deal with solid support. Oral medications are available starting from $69/month with a 10-month plan paid up front in full. Monthly treatment costs range from $69–$1899/month (flat fee), depending on your medication type. Currently, Hers offers a range of GLP-1s in the form of injectables and oral medications, and it’s available in all states. And our journey to create a better future of healthcare together is just getting started. Nutrition is crucial to healthy and sustainable weight management, but it can often go overlooked by individuals trying to stay on top of it on their own. And, most importantly, every person should be able to access that care. That shift puts more weight on newer initiatives like Labs, menopause care and international expansion to carry near-term excitement, while also raising questions about margin durability and regulatory oversight. To own Hims & Hers Health today, you have to believe its direct-to-consumer telehealth model can keep attracting and retaining patients even as growth expectations cool and competition heats up. Consumers will also be able to track their weight loss progress, as well as their water intake, exercise and sleep. See the full report here to find out more about how people are thinking about weight in America today. We know that weight loss is not one-size-fits-all. Hims & Hers offers prescription weight loss medications, including⁚ In the process, the company slams what it says is a “broken” health care system designed to keep patients “sick and stuck.” “Hims’ Super Bowl ad does not promote a specific drug or medication and therefore is not required to provide information about side effects or risks," he added. "Instead, it encouraged viewers to consult with a healthcare provider, which aligns with the FTC's guidelines for non-specific, "help-seeking" advertisements." Unlike Ozempic and Wegovy, Hims & Hers' weight loss drug is compounded and is not required to go through the FDA's rigorous approval process. When it comes to compounded weight loss medications, it's important to note that they aren't FDA-approved. It’s important to confirm the identity of the healthcare provider you're receiving care from and their medical background, qualifications and years of experience treating and counseling weight loss patients. While these breakthrough treatments can significantly improve health outcomes, our patients and people on forums like Reddit share mounting concerns about accessibility. “You’re not getting through this $4.5 trillion health care mess with traditional models of care,” he said. Traditional medical practices are getting a lift from newcomers seeking to fill gaps in what health industry executives described Monday as a lagging health care system. “Once I get to a healthy weight, I might start looking at other options just because it would be nice to go off of the medicine and just manage it through diet and exercise.” Baird understands that medication for weight management is not for everyone. Pricing Models and Insurance Coverage The essential daily round-up of fashion news, analysis, and breaking news alerts.Plus, access one complimentary BoF Professional article of your choice, each month. In addition to height, weight and medical details, users are also assessed based on sleep, stress and eating habits. The essential round-up of fashion news, analysis, and breaking news alerts.Plus, access one complimentary BoF Professional article of your choice, each month. Persistent side effects, like nausea—one of the primary reasons nearly 30% of patients on commercially available GLP-1s quit within the first month—can mean the difference between staying on track and giving up1. The senators said they believe the FDA may have the authority to take enforcement actions against marketing that could mislead patients, and they plan to introduce new legislation to address regulatory loopholes. Compounded products can also be produced when brand-name treatments are in shortage. Hims & Hers sells compounded semaglutide for under $200 a month. In its Super Bowl debut, the direct-to-consumer telehealth provider points out that 74% of U.S. citizens are overweight, and more than 500,000 die from causes related to obesity each year. Novo Nordisk will continue to sell Wegovy on other telehealth platforms that "share our commitment to patient safety," said Dave Moore, executive vice president at Novo Nordisk, in the company's statement. "U.S. patients should not be exposed to knock-off drugs made with unsafe and illicit foreign ingredients," Novo Nordisk said. This followed an order from the FDA that sought to restrict compounding pharmacies from selling copycat weight-loss drugs, a move that's expected to drive up prices. In offering the drug through more retailers, Novo Nordisk said it wanted to shift patients from using "knock-off, compounded versions" of Wegovy to the Food and Drug Administration-approved semaglutide drug. Experts say the company could land itself in court if it continues offering compounded products Both Noom and Hims & Hers offer access to GLP-1 medications to those who clinically qualify. Both Noom and Hims & Hers can help those who clinically qualify gain access to GLP-1 medication, if appropriate, but they differ in other program offerings. You’ll learn how they stack up on coaching, GLP-1 medication access, pricing, and support, so you can choose the approach that best fits your goals. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The results our customers are achieving show this approach is how to deliver the kind of impact our customers deserve. For others, it might mean working with their care team to better understand their diet, exercise, and behavioral patterns in the app. And behavioral support helps form lasting habits that create real, lifelong change. Medication helps the body manage the biological factors that affect weight. In a January release, the FDA said patients should not use a compounded GLP-1 drug if an approved drug, such as Wegovy, is available.The American Medical Association, the nation’s largest physician group, came out in support of a ban in 2015, citing TV advertising’s role in “inflating demand for new and more expensive drugs.”Novo Nordisk produces both drugs.To be sure, the Food and Drug Administration warns that patients should not use compounded drugs when approved drugs are available to patients.“There is advice everywhere, coming from all sides, about how to lose weight.That meant Hims & Hers had to largely stop offering the compounded medications, though some consumers may still be able to access personalized doses if it's clinically applicable. There is more focus than ever before on longevity and increasing our healthspan, or the period of our lives that we spend in good health. This affects how people spend their time, what they spend their money on, and so much more. The spot skewers outdated technology while introducing the business software company to a mass audience The model and reality TV personality pokes fun at herself in betting platform's first Big Game buy And though the company is pitting itself against pharmaceutical giants, its Super Bowl ad is still part of a trend that helped bring about the shortage in the first place. Novo Nordisk's move to dissolve the partnership came less than two months after the companies said they were entering a "long-term collaboration" to make obesity treatment more accessible. The Danish drugmaker said Monday that Wegovy will no longer be available on Hims & Hers and that it is ending the collaboration because the San Francisco-based online health company sold "illegitimate, knockoff versions of Wegovy that put patient safety at risk." Famed for speedy weight loss, the effects of the prescription-only drug are now shifting beauty standards. However, it is now clear that the portfolio of GLP-1 drugs will remain in shortage for some amount of time – and at Hims & Hers, we believe any amount of time is too long to wait for the care you deserve and the treatments you need. Hims & Hers today released a white paper on how its customers are thriving and seeing meaningful results through personalized weight loss solutions Launching its Weight Loss Programme marks the company’s continued progress in its mission to make personalised care accessible to millions of people across the UK. Hers’ customers receive ongoing clinician support through follow-ups and asynchronous messaging, along with treatment adjustments when necessary, keeping care seamless, conversational, and customer-centered. Delivering on our vision for safe and affordable access to GLP-1 injections took us over a year because our diligence required vetting dozens of manufacturers across the country with a wide range of expertise and safety standards. We never prioritize being first to market, but instead, always aim to offer an affordable, safe, and effective solution for our customers that meets the high standards they’ve come to expect from us. Please seek medical advice before starting, changing or terminating any medical treatment. USA Rx is not offering advice, recommending or endorsing any specific prescription drug, pharmacy or other information on the site. This information is for informational purposes only and is not meant to be a substitute for professional medical advice, diagnosis or treatment. Hims & Hers Health, Inc., the leading digital health and wellness platform, today announced its plans to bring its affordable, holistic weight loss program to Canada, timed with the anticipated first-ever availability of generic semaglutide anywhere in the world. This news has highlighted the disruptive role of companies like Hims & Hers, which offer patients access to more affordable, compounded versions of GLP-1 medications. Since its online debut late last month, the one-minute ad pitching the company’s legal knockoff of the weight-loss drug Wegovy has stoked the controversy over the high costs of a new generation of obesity treatments. Hims & Hers Health CEO and co-founder Andrew Dudum discusses the telehealth companys weight loss platform on The Claman Countdown. "Novo Nordisk is firm on our position and protecting patients living with obesity. When patients are prescribed semaglutide treatments by their licensed healthcare professional or a telehealth provider, they are entitled to receive authentic, FDA-approved and regulated Wegovy," Dave Moore, Novo Nordisk's executive vice president of U.S. Stopping weight loss treatment has been shown to result in weight regain. “Hers delivers a healthcare experience designed specifically for women and working to ensure all women have access to personal, comprehensive care is a powerful way to help each individual woman feel better in every aspect of her life,” says Dr. Jessica Shepherd, Hers’ Chief Medical Officer. Once that’s complete, you will get connected with a healthcare provider licensed in your state to start your diagnosis and explore potential treatments. A release on Durbin's website says that the ad in question appears to exploit a loophole "regarding promotions of compounded drugs by telehealth companies." Food and Drug Administration on Friday expressing concerns over an "upcoming advertisement" that "risks misleading patients by omitting any safety or side effect information when promoting a specific type of weight loss medication." Hims & Hers uses compounded semaglutide only from FDA-regulated bulk outsourcing facilities, said Dr. Craig Primack, the company's senior vice president of weight loss. It's crucial to consult with a qualified healthcare professional to determine if these medications are appropriate for you. While prescription weight loss medications can be effective for some individuals, they are not without potential risks and side effects. It’s about feeling better, being healthier, and being able to do things.” Baird wants to remind her colleagues and friends that “nobody looks at you sideways” for going on medication for a host of other conditions, she says. “What I found is that it’s sort of broken a lot of the stigma internally, where now other people talk to me about it, too. In this way the company seeks to reach those who use Google or social media as a first resource for medical issues. The move comes as the company focuses on personalization and customer choice in an effort to improve what was traditionally a “paternalistic” medical system, said Dr. Patrick Carroll, Hims & Hers chief medical officer, at Fortune’s Brainstorm Health conference in Dana Point, Calif. Since being on the GLP-1 program for the last 11 weeks, Baird has lost 17 pounds. Still, her insurance would not cover the medication because she did not also have a chronic condition, like diabetes. Two years ago, Baird asked her doctor about access to GLP-1s. The support you receive differs greatly between programs.GLP-1 medications were originally developed to treat type-2 diabetes and obesity and went through extensive clinical trials before being approved.The senators said they believe the FDA may have the authority to take enforcement actions against marketing that could mislead patients, and they plan to introduce new legislation to address regulatory loopholes.No two people are the same, so the Company provides access to personalized care designed for results.According to Novo Nordisk, over 55 million Americans have commercial insurance coverage for Wegovy, with around 90% of those people paying $0 to $25 per month for the medication.The impressive results seen in clinical studies and real-world experiences highlight the potential of these injections to make a significant impact on weight loss journeys.The ongoing shortage of GLP-1 medications is placing an immense strain on the millions of Americans who have obesity, are looking for help, and cannot access the care that they deserve. No hidden fees, no buried fine print, just complete transparency about who you can trust with your health AND your wallet. The telehealth provider landscape is a mess. Hers and Hims offer nutrition, sleep, and exercise coaching, which will help prevent regaining weight. However, most medication plans, especially for brand-name options, are prepaid and non-refundable. These are FDA-approved but much more expensive than compounded versions, and you’ll need to pay up front. Hims & Hers Health (HIMS) announced that Hims & Hers customers will now be able to supplement their treatment plan with daily meal replacement bars and shakes to support them on their comprehensive weight loss journey. During the company's quarterly call with investors in February, Hims & Hers said its weight loss offerings will primarily consist of its oral medications and liraglutide. That meant Hims & Hers had to largely stop offering the compounded medications, though some consumers may still be able to access personalized doses if it's clinically applicable. In May, Hims & Hers started prescribing compounded semaglutide, the active ingredient in Novo Nordisk's GLP-1 weight loss medications Ozempic and Wegovy. Earlier this year, a Super Bowl ad from the company touted the benefits of its weight-loss medications but didn’t list any of their side effects or potential harms. Almost two thirds of adults in Canada are overweight or living with obesity, yet access to proven treatments remains limited due to high costs and availability. Hims & Hers' entry to Canada will come as generic semaglutide hits the market for the first time, marking a major step in expanding access to affordable weight loss care The drugs have surged in popularity in recent years as people touted the drugs' weight-loss effects. GLP-1 agonists are a class of Type 2 diabetes drugs that improves blood sugar control but may also lead to weight loss. In 2012, unsanitary conditions at a compounding pharmacy caused a 20-state outbreak of fungal meningitis that killed 64 people and infected nearly 800 others. Looser labeling requirements for compounded versions of GLP-1s can also lead to confusion about dosage, according to an FDA alert issued in July 2024. If there's a problem, it's more difficult to pinpoint who's liable, and more challenging to investigate if more users of the drug might be impacted. For example, they might make a liquid version of a drug only available in pill form for a patient who can't swallow pills, or they might replace a non-active ingredient for a patient with an allergy to it. “Hims & Hers clearly understands that they need to explain these critical facts to consumers because they include a disclaimer,” Safdar wrote. In a Feb. 5 letter to the agency, Shabbir Imber Safdar, executive director of the Partnership for Safe Medicines (PSM), called the ad “blatantly misleading,” noting its written warning doesn’t cut it. With Super Bowl LIX looming, health advocacy groups are calling on the FDA to prevent “Sick of the System” from airing Feb. 9. Hims & Hers is hardly the only company that swooped in when name-brand GLP-1s were in short supply. Though compounded semaglutide, for example, contains the same active ingredient as Wegovy, the Food and Drug Administration doesn’t verify the safety, quality, or effectiveness of such mixed or altered meds. The FDA does not review the safety and efficacy of compounded products, which are custom-made alternatives to brand drugs designed to meet a specific patient's needs. When those medications are in shortage, certain manufacturers can prepare a compounded version if they meet U.S. The GLP-1 market, dominated so far by pharmaceutical giant Novo Nordisk, has faced supply constraints in recent months as the drugs get expanded approval from health regulators and increased health coverage. The company's oral medication kits start at $79 a month, and its compounded GLP-1 injections will start at $199 a month. Hims & Hers said it plans to make branded GLP-1 medications available to its customers once supply is consistently available. The growing community of Hims & Hers weight loss customers are feeling healthier and achieving meaningful personal goals that transcend numbers on the scale. “The data and insights we have been able to glean through our research show that our customers are having meaningful health outcomes when it comes to weight loss,” said Dr. Jessica Yu, Senior Director of Patient Experience at Hims & Hers. Since December 2023, Hims & Hers has provided its customers access to weight loss solutions. The research also suggests that Hims & Hers’ weight loss offering is sustainable, allowing its customers to stay on their treatments and achieve lasting results. Both are from the same parent company. To understand what that means for safety, see the treatment options section. That said, many of the more affordable options from Hers involve compounded GLP-1s, which aren’t FDA-approved. Yes, Hers partners with licensed medical providers and certified pharmacies, which helps ensure your treatment is medically supervised and legally compliant. Then take control of your health with Hers and Hims. Patients can check the testing related to their batch of medication on the company's app, Primack told Live Science.And the top desire for a weight loss plan, according to Americans, is “That it’s simple to follow.”Then take control of your health with Hers and Hims.Oral medications are available starting from $69/month with a 10-month plan paid up front in full.Unfortunately, the company is peddling short-term solutions to people who face a long-term struggle.Medication targets biological factors, nutrition fuels the body, physical activity builds strength and resilience, and behavioral support fosters lasting habits.Noom combines medical treatment with education, coaching, and sustainable lifestyle change to provide a strong foundation for success.But the company's gross margin, or the profit left after accounting for the cost of goods sold, was 77%, disappointing analysts who were expecting 78.4%, according to StreetAccount. However, these medications are not available on the platform at this time but may become available in the future, said Melissa Baird, chief operating officer of Hims & Hers. The first is access to medication, which can include personalized combinations of Bupropion, Metformin, Naltrexone and Topiramate with Vitamin B12. If considered appropriate, the patient will then receive a personalized treatment plan that is based on several factors, including the person’s body, health history and goals. In a January release, the FDA said patients should not use a compounded GLP-1 drug if an approved drug, such as Wegovy, is available. Understanding Weight Loss⁚ A Holistic Approach Leaders are often encouraged to bring their whole selves to the office, and Baird believes that being vulnerable about her health journey propels her on that track.” The blockbuster obesity medication sold by Novo Nordisk can lead to 15% weight loss, more actors claim.Just as importantly, 75% of customers remained on treatment plans in the same timeframe, a powerful signal of real-world trust and clinical success.There are medications that work, but they’re priced for profits, not patients.”In a recent interview, Esperion president and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company’s expansion into new diseasesHowever, the weight loss stalled, and no amount of diet and exercise was working.Expert #2 offered a more nuanced perspective, suggesting there might be a legitimate case for compounding GLP-1s under 503A for specific patient groups, even if the drugs are not individually tailored.Hims & Hers Health is now in the weight loss business. Hims & Hers says its GLP-1 medications contain the same active ingredients as its rivals, but the price starts at $199 per month. The firm’s analysts warn of a drastic cooling in the telehealth company’s business dynamics. The FDA has declared the shortages as "resolved," removing the drugs from its shortage list. GLP-1 medications can support healthy weight loss along with a reduced calorie diet and increased exercise by helping manage blood sugar levels, curb cravings and suppress appetite, so people eat less without feeling deprived. Customers can access the compounded GLP-1 medications via a prescription from a licensed health-care provider on the Hims & Hers platform. The ad claims those drugs are "priced for profits, not patients" and points to Hims & Hers' weight loss medications as "affordable" and "doctor-trusted" alternatives. A telehealth company that sells a compounded version of medications used for weight loss has found itself at the center of an escalating controversy over an advertisement that aired during the 2025 Super Bowl. Throughout my 20 years of medical experience in obesity care and working with thousands of patients, I have seen first-hand the difference that a comprehensive, individually-tailored treatment approach makes in people’s weight loss journeys. Enter Hims & Hers, a company offering a range of products aimed at both men and women, including weight loss solutions. “Especially because so many people are on all kinds of different medications, and there’s no discussion of the potential interaction effects here.” The company is marketing the product as a cheaper alternative to the pair of drugs, which are currently in short supply. Shares of the company closed up more than 27% Monday. To capture sentiments about how weight shapes America, we conducted a nationally representative online study among 5,000 adults 18+. Americans are looking for solutions that work, 74% have weight maintenance on their mind, either actively (29%)1 or passively (45%)2. 85% of respondents said at least one aspect of their life would improve if they lost weight. Weight stability, or body sustainability, is recognized as a first stop in increasing life expectancy and stretching out our healthy years. The analyst note also highlighted specific worries about the men's sexual health business, expecting it to be a drag on growth in the first half of 2026. Hims did not provide financial terms of the deal, but a company spokesperson said these details will be shared with its second-quarter results expected in August. The telehealth firm's shares, which have dropped nearly 9% in the last two weeks, rose 6.15% to $60.26 in premarket trading. But one spot, from telehealth company Hims & Hers, sought to capitalize on the Monday morning misgivings many of us may have after an evening of gridiron gluttony. Semaglutide, which is the active ingredient in Novo Nordisk's Wegovy and Ozempic, as well as tirzepatide, which is the active ingredient in Eli Lily's Mounjaro and Zepbound, are considered GLP-1 drugs. "We’re passing that access and value along to our customers, who deserve the highest standard of clinical safety and efficacy to meet their goals, and we're doing it in a safe, affordable way that others can’t deliver." Novo Nordisk produces both drugs. A Blue Cross study unrelated to Hims & Hers found that 30% of patients on commercially available options discontinued their treatment in the same time frame. Additionally, 92% of oral medication users and 93% of GLP-1 users at Day 56 reported feeling healthier, experiencing improvements in health conditions, confidence, and mood. Our platform also provides nutrition, exercise, mental health resources, sleep guidance, and progress tracking for hydration, movement, and sleep—all within the Hims & Hers app. "We’ve leveraged our size and scale to secure access to one of the highest-quality supplies of compounded GLP-1 injections available today," Hims & Hers co-founder and CEO Andrew Dudum said in a statement announcing the new drugs. Hims & Hers is offering injectable weight loss drugs at a fraction of the price of competitors. Health platform Hims & Hers Health Inc. announced Monday that it's rolling out injectable weight-loss drugs that cost a fraction of the price of competitors Wegovy and Ozempic. Hims & Hers is adapting to the modern patient by publishing content on symptoms that educate people and help bring them into the company’s platform. In the past, doctors dictated many aspects of a person’s health, something that doesn’t fit well with the freedom of choice that patients expect from their health care today, Carroll said. And she plans to stay on the medication until she gets to a healthier weight and says she will continue sharing her experience along the way. “I know that being at the weight that I was was not a healthy state, and I was probably going to develop one of those chronic conditions.” It’s almost like a little support group at work where they’re like, ‘Oh yeah, I’m on the week whatever of the titration.’ I find that people are actually excited to talk about it because it does work.” “I crossed the barrier into the 40s, so losing weight started getting a little more difficult,” Baird, now 46, says, recalling that it was much easier to maintain a healthy weight in her 20s. The commercial is an extension of ads released throughout 2024 by Hims & Hers’ creative team and its chief design officer, Dan Kenger, as the company moved into the GLP-1 market. Off-screen, the company compared the 42% of TV households that watched the Super Bowl last year to the 40% of U.S. adults diagnosed as obese by September 2024. Among the telehealth companies Novo Nordisk partners with are LifeMD and Ro. Novo Nordisk said it began selling Wegovy via telehealth companies, including Hims & Hers, after a nationwide shortage. As somebody who’s struggled with obesity myself, I have tried a whole lot of those things. “There is advice everywhere, coming from all sides, about how to lose weight. Primack is an obesity medicine certified physician and the founder of the Scottsdale Weight Loss Center in Arizona. While telehealth offers convenience, there are distinct advantages to working with a weight loss doctor right here in New Jersey. Many telehealth and medspa companies advertise "healthcare providers" for treatment, but often you may never see this provider or only communicate via text with them. Based on a Wegovy® clinical study in adults with obesity or overweight and weight-related medical problems, mean weight loss achieved at 2 years was 15.2% vs. 2.6% for placebo. Included in that price is access to Hims & Hers’ world-class, holistic approach to weight loss, powered by today's technology. “This is another example of how we’re working together with the industry to bring people closer to the care and treatments they need.” “In my mind, I’m a little immune to that because I just don’t see how you wanting to be a better, healthier person that can chase your baby nephew around the living room floor is a bad, shameful thing.” “I have a really hard time understanding the argument where you would shame someone for wanting to be a healthier person. People who take them have admitted feeling criticized for not having the willpower to lose weight on their own. “We are always looking for long-term, sustainable ways to increase access to care for our customers,” said Andrew Dudum, CEO and co-founder of Hims & Hers. According to the World Health Organization (WHO), around 70% of American adults have obesity or are overweight and at least 2.8 million people die each year due to being overweight or having obesity. This kind of marketing also undermines public trust in healthcare systems and telehealth platforms. Due to overwhelming demand and supply shortages, many telehealth platforms began offering compounded versions through partner pharmacies. At the New Jersey Bariatric Center®, we've found that sustainable weight loss comes from a holistic approach. With monthly classes on nutrition and support group meetings, patients have the resources they need. They meet one-on-one with our patients to craft personalized nutrition and meal plans that fit their lifestyles. Without insurance coverage, the cost of medications like Ozempic and Wegovy can run more than $1,000 a month. “This distinction is important because compounded drug advertisements fall under FTC jurisdiction, not the FDA's typical prescription drug advertising rules,” Brunner said in the statement. After a year of evaluating this space with our clinical partners, we believe we can deliver equal – if not better – experiences for the millions of people who deserve to find success with a solution that has been personalized for their needs. We have taken a holistic approach to weight loss because we are committed to providing a comprehensive set of options so individuals and their providers can find a solution that is right for them. Just as importantly, 75% of customers remained on treatment plans in the same timeframe, a powerful signal of real-world trust and clinical success. “The demand for simpler, more personalized healthcare is universal,” said Andrew Dudum, founder and CEO of Hims & Hers. To ensure a world-class and localized experience, this expansion will include access to British, German, and French healthcare providers in local languages. This acquisition is expected to accelerate Hims & Hers' vision to deliver the same seamless, personalized care experience it has successfully built in the U.S. to millions more people globally. At Hims & Hers, we are in constant pursuit of elevating how we serve our customers by finding more ways to make achieving their health and wellness goals more accessible and sustainable. The FDA permits so-called compounding, or customized production, when there is a shortage of the official versions of FDA-approved medications. Regulators said the 42-minute TV segment from Eli Lilly and Novo Nordisk gave a “misleading impression” about the safety of Zepbound, Wegovy and similar “drugs with multiple serious, potentially life-threatening risks.” The FDA also posted separate warning letters to manufacturers of the so-called GLP-1 drugs, taking issue with a 2024 infomercial featuring Oprah Winfrey. It’s the first FDA attempt to directly police online platforms like Hims, which have long argued they’re not subject to traditional drug advertising rules. Demand for GLP-1 drugs, which are used to treat diabetes and weight loss, has surged in recent years, with one in eight U.S. adults saying they've used the treatments, according to health research publisher KFF. Prescription weight loss medications can have potential side effects, and their use should be carefully considered in consultation with a healthcare professional. "The FDA's compounding program aims to protect patients from poor quality compounded drugs, while preserving access to lawfully marketed compounded drugs for patients." The company says it also offers a savings program that brings the cost of a 28-day supply of Wegovy to $650 for those without insurance coverage. According to Novo Nordisk, over 55 million Americans have commercial insurance coverage for Wegovy, with around 90% of those people paying $0 to $25 per month for the medication. Insurance coverage for the medications varies, depending on everything from a person's medical diagnosis to where they live and their insurance plan. The agency does not review compounded GLP-1 medications for safety, and said it has received "adverse event reports" from patients who have used compounded semaglutide medications. To be sure, the Food and Drug Administration warns that patients should not use compounded drugs when approved drugs are available to patients. It already has an existing weight-loss program that is on track to bring in more than $100 million in revenue by 2025, with the program selling oral weight-loss medications for about $79 per month. The startup said its GLP-1 injectable drug, which is made in partnership with a manufacturer of compounded injectable medications, will have "consistent" availability. GLP-1 drugs, which stands for glucagon-like peptide 1 agonists, help people feel fuller and less hungry, aiding their efforts to lose weight. Through our offering, we’re delivering a personalized approach for every customer that is affordable and built to deliver successful outcomes. Over the last year, we have grown in our conviction – based on our medical experts’ evaluation and the strength of our infrastructure – that if done properly, compounded GLP-1s are safe and effective. Drugs that currently cost thousands out of pocket for a monthly supply can be accessed for much, much less – and at Hims & Hers we believe those savings should be passed to consumers. We knew GLP-1s were not for everyone and the shortages across the industry made GLP-1s too expensive and too challenging to physically access. However, in contrast with mainstream drug commercials that ambush consumers with a catalogue of side effects, “Sick of the System,” in a blink, flashes text saying its compounded products aren’t FDA-approved. “As a brand that customers trust, we’re using the voice that we’ve built over the last seven years to raise awareness to this critical health issue,” Hims & Hers said in a Jan. 31 statement to Fortune, three days after the ad launched on YouTube. In America, as the commercial highlights, about 74% of adults 20 and older had overweight or obesity as of the 2017–18 National Health and Nutrition Examination Survey. As of 2022, one in eight people worldwide was living with obesity, according to the World Health Organization. This split represents the latest challenge facing Hims & Hers, even as the company aims to achieve $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA by 2030. The company’s stock has plummeted approximately 18% over the past month, reflecting recent challenges. Click here for access to our special report that reveals one profitable leader already riding this wave, it’s free. Additionally, the firm cited weak third-party sales data and potential risks to the company's profit margins as near-term issues. The treatment plans have three elements. Compare that to more than 20 years ago when a little over 30% struggled with obesity. About 42% of U.S. adults struggle with obesity, according to the Centers for Disease Control and Prevention. In a recent interview, Esperion president and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company’s expansion into new diseases The company plans to offer updated guidance in its next earnings report. You may have questions about how these programs work in practice, and these common questions about Noom vs Hims & Hers can help guide your choice. Both make sign-up straightforward, but they differ in how much behavioral support is built in. Eligibility is based on individual health history and medical guidelines. Noom combines medical treatment with education, coaching, and sustainable lifestyle change to provide a strong foundation for success. We’ll explore pricing models, insurance coverage, and potential savings through telehealth providers. The choice between compounded and brand-name options depends on individual circumstances, including budget constraints, medical history, and risk tolerance. For example, Hims & Hers Health’s compounded semaglutide injectable is priced at $199 per month, an 85% discount from Novo Nordisk’s Ozempic and Wegovy. This innovative approach to shedding excess weight has been gaining traction, promising results where traditional methods have fallen short. "We will have to start notifying customers in the coming month or two that they will need to start looking for alternative options on the commercial dosing," Hims & Hers CEO Andrew Dudum said on the call. Early customer results indicate they are managing side effects well, staying on treatment, and overall feeling healthier. Because at the end of the day, we’re not just helping people lose weight. For everyone, it means consistent, 24/7 access to their care team and their entire holistic toolkit, without interruption or arbitrary barriers to care. Our weight loss patients in New Jersey, along with many online communities, are grappling with the realities of GLP-1 medications like Wegovy® and Zepbound®. The ad criticizes our healthcare system’s barriers to obesity treatment, including high medication costs and limited insurance coverage. Hims & Hers provides increased access to safe and affordable weight loss treatment at up to a 50% discount to help the heroes in their communities with their health and wellness. Analyst Craig Hettenbach says that Expert #1 cautiously advised compounding pharmacies to cease large-scale production of GLP-1 drugs once the shortage ends, acknowledging that business owners have varying levels of risk tolerance. By partnering with a popular telehealth company, Novo could speed up Wegovy's adoption, leading to more prescriptions. The move comes as Hims is adjusting to a regulatory ban in the United States on manufacturing mass copies of Novo Nordisk's popular weight-loss drug Wegovy, that took effect on May 22. Consider working with a dietitian who understand these gender-specific needs, and remember that the best approach is one that you can maintain long-term while supporting your overall health and happiness. Understanding his vs. hers weight loss differences is just the beginning. “We are shifting the paradigm in weight loss to help people curb cravings, decrease binge eating and maintain a healthy lifestyle with a program unlike any available. Each individual treatment plan is personalized by licensed healthcare providers on the Hims & Hers platform based on a person’s body, health history and overall health and wellness goals. Weight Loss by Hims & Hers is designed to help people achieve and maintain their weight-loss goals with personalized and affordable clinical programs that combine medication management, digital tracking tools, and customized educational content. Among the latest company announcements, the release of clinical data highlighting strong patient engagement and weight loss success from compounded GLP-1 therapies stands out. Hims & Hers Health shares are under pressure largely because the firm sells cheaper, compounded versions of popular weight-loss drugs. Eli Lilly’s tirzepatide, marketed as Zepbound for people with obesity and Mounjaro for those with Type 2 diabetes, is another story. Novo Nordisk’s liraglutide, indicated for weight loss as Saxenda and for Type 2 diabetes as Victoza, has been on the list since July 2023. Novo Nordisk’s semaglutide, marketed as Wegovy for people with obesity and Ozempic for those with Type 2 diabetes, has been on the FDA Drug Shortages list since August 2022. But GLP-1 medications — such as Ozempic and Wegovy, which have skyrocketed in popularity — were not previously offered as part of that program. In addition to the quantitative study, we moderated five, 45-minute Zoom interviews with weight loss experts, including Hims & Hers medical professionals and health and wellness influencers with diverse opinions on weight loss and wellness. From mental health, to weight loss, to everything in between, we celebrate every aspect of their wellness journeys. Always consult a licensed healthcare provider before starting or changing hormone therapy. Semaglutide reduces body weight by around 14% on average, while tirzepatide in clinical trials has shown up to 20% weight loss on average. The most effective FDA-approved options for weight loss are tirzepatide (Mounjaro/Zepbound) and semaglutide (Ozempic). Melissa Baird, a health care executive based in Seattle, knows first-hand the stigma around weight at work. Today, we are helping more than 1.7 million customers treat a chronic illness impacting their life, and over 600,000 of those customers are being treated with a personalized treatment regiment. We’ve found both customers and providers love this flexibility, as it allows for nuanced clinical decision-making that we believe is at the core of helping customers stick to medication regimens and supporting successful outcomes. We’ve offered access to personalized medicine through compounding for nearly 6 years as a way to help providers individualize care to meet customer needs. In our Shape of America report released last December, we asked Americans which areas of their life have been impacted, either positively or negatively, by their physical fitness or weight. We know weight weighs heavily on the minds and moods of Americans. The United States is in the midst of an obesity epidemic. This support helps them stay on track for long-term success. When you consume more calories than you burn, your body stores excess energy as fat, leading to weight gain. For consumers interested in Wegovy and Ozempic knock-offs, Glowacki recommends consulting with a health professional before they make a purchase. “On the one hand, it’s good to encourage conversation around some of these more stigmatized issues, such as mental health,” Glowacki says. The ad comes amid a broader antiestablishment shift in public health with the appointment of Robert F. Kennedy Jr. to Health and Human Services Secretary. Ondansetron is just one example of how we’re making care even more personalized and accessible for patients. For others, it’s practical tools like meal kits, to make healthy eating more accessible during their weight loss journey. For some customers, this means making available personalized GLP-1 medications, so their provider can tailor dosing to minimize side effects and maximize results. Our weight loss program is about so much more than numbers on a scale—it’s about creating sustainable pathways to lasting health. Unlike traditional care models that often leave patients to navigate treatment alone, Hims & Hers delivers access to a holistic weight loss program that combines personalized dosing when clinically necessary, 24\/7 care team access, and educational support across nutrition, mental health, and physical wellness. Unlike traditional care models that often leave patients to navigate treatment alone, Hims & Hers delivers access to a holistic weight loss program that combines personalized dosing when clinically necessary, 24/7 care team access, and educational support across nutrition, mental health, and physical wellness. "Bringing our trusted, comprehensive approach to the UK will help people lead fuller and healthier lives. And with the launch of the Hers platform, we are ensuring women have access to the dedicated, personalised care they need. Pairing clinically-proven treatments like GLP-1s with holistic support across nutrition and exercise helps make sustainable weight management achievable for the millions battling obesity today." “The data shows our customers are experiencing good weight loss on compounded medications, having manageable side-effects through personalized dosing, suggesting the treatment is sustainable and they are making positive strides towards a healthier future. Having her plan tailored to her needs alongside 24/7 access to a dedicated care team has helped Kimberly feel supported on her journey. Beyond the significant weight loss on the scale, Zach reports feeling better and healthier than ever. Like with every health category we offer our customers, we are committed to building a treatment solution that includes safe and affordable ingredients that are consistently available and effective.